Aprogen KRX:007460KOSPI
에이프로젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked8since Sep 11
In Q2 2026, Aprogen reported revenue of ₩35.5bn, up 47.0% year on year, and an operating loss of ₩22.4bn. Aprogen (에이프로젠) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Revenue +30% Major holder adding M&A / stake deal 4 quarters of losses Screener
Aprogen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩35.5bn | +47.0% | −₩22.4bn margin −63.2% | −₩42.3bn |
| Q1 2026 | ₩36.3bn | +35.8% | −₩20.6bn margin −56.8% | −₩28.1bn |
| Q4 2025 derived | ₩31.5bn | -20.5% | −₩26.9bn margin −85.4% | −₩34.5bn |
| Q3 2025 | ₩35.6bn | -3.4% | −₩22.3bn margin −62.7% | −₩33.7bn |
| Q2 2025 | ₩24.2bn | -32.1% | −₩23.9bn margin −98.9% | −₩42.2bn |
| Q1 2025 | ₩26.7bn | -29.8% | −₩22.5bn margin −84.1% | −₩30.1bn |
| Q4 2024 derived | ₩39.6bn | +6.0% | −₩29.1bn margin −73.4% | −₩41.4bn |
| Q3 2024 | ₩36.8bn | -7.7% | −₩22.0bn margin −59.9% | −₩21.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Aprogen top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Aprogen news Korean headlines
-
에이프로젠 자회사 앱튼, 혈액암 신약 GPC-100 글로벌 임상 3상 추진"
1 more on this story · 1 outlets
- 앱튼, 혈액암 신약 'GPC-100' 글로벌 3상 착수...인허가 절차 돌입글로벌경제신문 · Sep 17 11:53
-
앱튼, GPC-100 글로벌 3상 준비 본격화…에이프로젠 임상팀 가동
5 more on this story · 5 outlets
- 앱튼, 'GPC-100' 글로벌 임상 3상 본격 착수…에이프로젠 임상팀 구축머니투데이 · Sep 17 10:53
- 앱튼, 'GPC-100' 글로벌 임상 3상 추진…에이프로젠 임상팀 가동데일리한국 · Sep 17 11:23
- 앱튼, GPC-100 글로벌 임상 3상 착수∙에이프로젠 임상팀 전격 가동바이오타임즈 · Sep 17 11:31
- 앱튼, 'GPC-100' 글로벌 3상 채비…에이프로젠 임상팀 투입파이낸셜뉴스 · Sep 17 11:34
- 앱튼, ‘GPC-100’ 글로벌 3상 준비 본격화…FDA 협의 추진메디컬투데이 · Sep 17 13:14